2024
Saturday, July 13, 202411:30 AM - 12:30 PMGSOR01 Presentation Time: 11:30 AM A Prospective Clinical Trial Assessing Comfort of Brachytherapy with a Novel Tapered Vaginal Applicator
Mahal A, Yu J, Mahal R, Tien C, Adefres B, Damast S. Saturday, July 13, 202411:30 AM - 12:30 PMGSOR01 Presentation Time: 11:30 AM A Prospective Clinical Trial Assessing Comfort of Brachytherapy with a Novel Tapered Vaginal Applicator. Brachytherapy 2024, 23: s72-s73. DOI: 10.1016/j.brachy.2024.08.099.Peer-Reviewed Original ResearchVisual-analogue-scaleVaginal brachytherapyVaginal stretchingVaginal applicationEndometrial cancerAssociated with less painIr-192 seedsDose fall-offClinically significant responseProspective clinical trialPatient-centered evaluationVaginal introitusProspective trialsDose distributionSurface doseVaginal mucosaIr-192Less painNarrow introitusPaired t-testEC patientsConsenting patientsClinical trialsIntroitusPatients
2023
The Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial Carcinoma
Patrich T, Wang Y, Elshaikh M, Zhu S, Damast S, Li J, Fields E, Beriwal S, Keller A, Kidd E, Usoz M, Jolly S, Jaworski E, Leung E, Taunk N, Chino J, Russo A, Lea J, Lee L, Albuquerque K, Hathout L. The Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial Carcinoma. American Journal Of Clinical Oncology 2023, 46: 114-120. PMID: 36625449, DOI: 10.1097/coc.0000000000000975.Peer-Reviewed Original ResearchConceptsStage IIIC endometrial carcinomaRecurrence-free survivalNon-black patientsParaaortic lymph nodesGrade 3 tumorsBlack patientsOverall survivalEndometrial carcinomaWorse OSLymph nodesNonendometrioid histologyPositive paraaortic lymph nodesRetrospective multi-institutional studyKaplan-Meier methodMulti-institutional studySPSS version 27Adjuvant chemotherapyConcurrent chemoradiotherapyHazard ratioRFS ratesClinical outcomesRandomized trialsNonsignificant trendPatientsPrognostic covariates
2022
Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic
Damast S, Tien CJ, Young M, Altwerger G, Ratner E. Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic. Journal Of Contemporary Brachytherapy 2022, 14: 66-71. PMID: 35233237, PMCID: PMC8867238, DOI: 10.5114/jcb.2022.113058.Peer-Reviewed Original ResearchOverall treatment timeHR-CTV DCervical cancerMucosal toxicityMedian high-risk clinical target volumeHigh-risk clinical target volumeCOVID-19 pandemicLocal control outcomesPre-COVID cohortClinical target volumeMagnetic resonance imagingGastrointestinal eventsRetrospective reviewCC patientsEarly outcomesCOVID groupMedian numberInpatient resourcesInterstitial brachytherapyGrade 2Local controlResonance imagingSeparate weeksTarget volumePatients
2021
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021.
Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Diver E, Fisher CM, Frederick P, Gaffney DK, George S, Giuntoli R, Han E, Howitt B, Huh WK, Lea J, Mariani A, Mutch D, Nekhlyudov L, Podoll M, Remmenga SW, Reynolds RK, Salani R, Sisodia R, Soliman P, Tanner E, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Motter AD. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 888-895. PMID: 34416706, DOI: 10.6004/jnccn.2021.0038.Peer-Reviewed Original ResearchRadiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer
Laird J, Leventhal J, Kanowitz J, Damast S. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer. Practical Radiation Oncology 2021, 11: 448-452. PMID: 34157449, DOI: 10.1016/j.prro.2021.06.001.Peer-Reviewed Original ResearchA phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)
Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals Of Oncology 2021, 32: 1045-1046. PMID: 33932502, PMCID: PMC9465821, DOI: 10.1016/j.annonc.2021.04.013.Commentaries, Editorials and LettersBenefits of a Multidisciplinary Women’s Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic Radiotherapy
Li JY, D’Addario J, Tymon-Rosario J, Menderes G, Young MR, Johung K, Ratner E, Minkin MJ, Damast S. Benefits of a Multidisciplinary Women’s Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic Radiotherapy. American Journal Of Clinical Oncology 2021, 44: 143-149. PMID: 33755031, DOI: 10.1097/coc.0000000000000800.Peer-Reviewed Original ResearchMeSH KeywordsAdultBrachytherapyCombined Modality TherapyDyspareuniaFemaleGenital Neoplasms, FemaleHumansInterdisciplinary CommunicationMenopauseMiddle AgedPatient SatisfactionPelvisRadiation InjuriesRadiotherapyRectal NeoplasmsRetrospective StudiesSexual Dysfunction, PhysiologicalSexual HealthTreatment OutcomeVaginal DiseasesWomen's Health ServicesConceptsPelvic radiotherapySexual health clinicsMenopausal symptomsPersistent menopausal symptomsSystemic hormone therapyFemale cancer patientsPatterns of careDilator therapyVaginal estrogenGastrointestinal malignanciesHormone therapyVaginal drynessMedian ageMultidisciplinary careRetrospective reviewFemale patientsTreatment patternsCancer patientsPatient satisfactionSexual symptomsTestosterone creamVaginal lubricantsHealth clinicsSTATA 13.1Patients
2020
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020.
Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. Journal Of The National Comprehensive Cancer Network 2020, 18: 660-666. PMID: 32502976, DOI: 10.6004/jnccn.2020.0027.Peer-Reviewed Original ResearchConceptsCervical cancerNCCN Guidelines InsightsSystemic therapy recommendationsTreatment of patientsHistopathologic classification systemNCCN guidelinesMetastatic diseaseDiagnostic workupEndocervical adenocarcinomaTherapy recommendationsPatientsCancerDiseaseRecent updatesClassification systemGuidelinesHPVAdenocarcinomaWorkupStagingRecurrent
2018
Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy
Stahl JM, Qian JM, Tien CJ, Carlson DJ, Chen Z, Ratner ES, Park HS, Damast S. Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy. Supportive Care In Cancer 2018, 27: 1425-1433. PMID: 30187220, DOI: 10.1007/s00520-018-4441-5.Peer-Reviewed Original ResearchConceptsVaginal stenosisEndometrial carcinomaMultivariable Cox proportional hazardsMultivariable Cox regression analysisVD useAcademic tertiary referral centerTertiary referral centerCox regression analysisLog-rank testCox proportional hazardsDevelopment of gradeDilator usePelvic radiotherapyReferral centerNoncompliant patientsPrimary outcomeAdjuvant brachytherapyEC patientsConclusionsThe riskRate brachytherapyProportional hazardsOptimal durationPatientsBrachytherapyStudy period
2017
Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer
Qian JM, Stahl JM, Young MR, Ratner E, Damast S. Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer. Journal Of Gynecologic Oncology 2017, 28: 0. PMID: 29027402, PMCID: PMC5641534, DOI: 10.3802/jgo.2017.28.e84.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBody Mass IndexBrachytherapyConstriction, PathologicDatabases, FactualEndometrial NeoplasmsFemaleGastrointestinal DiseasesGravidityHumansHysterectomyLymph Node ExcisionMiddle AgedNeoplasm StagingOvariectomyRadiation InjuriesRadiotherapy, AdjuvantSalpingectomyTreatment OutcomeVaginaVaginal DiseasesConceptsVaginal brachytherapyVaginal symptomsLate grade 3 toxicityEarly-stage endometrial cancerNormal body mass indexAdjuvant vaginal brachytherapyGrade 3 toxicityShorter vaginal lengthStage endometrial cancerEndometrial cancer patientsBody mass indexRate of recurrenceAcute gastrointestinalTreatment tolerabilityVaginal stenosisEndometrial cancerVaginal lengthMass indexRecurrence rateCancer patientsVaginal toxicityTreatment characteristicsHigh riskSide effectsPatients
2015
Influence of Robotic Hysterectomy on Delayed Vaginal Cuff Healing and Brachytherapy Initiation in Endometrial Carcinoma Patients
Stahl J, Park H, Damast S. Influence of Robotic Hysterectomy on Delayed Vaginal Cuff Healing and Brachytherapy Initiation in Endometrial Carcinoma Patients. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e256. DOI: 10.1016/j.ijrobp.2015.07.1192.Peer-Reviewed Original ResearchPredictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma
Park HS, Ratner ES, Lucarelli L, Polizzi S, Higgins SA, Damast S. Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma. Brachytherapy 2015, 14: 464-470. PMID: 25887343, DOI: 10.1016/j.brachy.2015.03.001.Peer-Reviewed Original ResearchConceptsVaginal stenosisDilator useIndependent predictorsEndometrial carcinomaTotal doseRate brachytherapyMultivariable logistic regression analysisExternal beam radiation therapyCommon Terminology CriteriaEffective adjuvant treatmentMonths of followupPost-treatment factorsBeam radiation therapyHigher total doseLogistic regression analysisTerminology CriteriaAdjuvant treatmentFollowup visitMean followupAdverse eventsLast followupMultivariable analysisRisk factorsRadiation therapyPatients
2006
Do metallic ports in tissue expanders affect postmastectomy radiation delivery?
Damast S, Beal K, Ballangrud Å, Losasso TJ, Cordeiro PG, Disa JJ, Hong L, McCormick BL. Do metallic ports in tissue expanders affect postmastectomy radiation delivery? International Journal Of Radiation Oncology • Biology • Physics 2006, 66: 305-310. PMID: 16904530, DOI: 10.1016/j.ijrobp.2006.05.017.Peer-Reviewed Original ResearchConceptsPostmastectomy radiation therapyTissue expanderTangent beamsPermanent implant exchangeDosimetric effectsChest wall treatmentMetallic portPermanent breast implantPotential dosimetric effectsMedian doseImplant exchangeEx vivo resultsThermoluminescent dosimetersRadiation therapyPatientsVolume of tissueBreast implantsRadiation deliveryPermanent implantsExit doseVivo resultsDoseMV photonsTreatmentImplants